Dental Care Clinics in Greenbrae, CA Accepting Medicare
5 Dental Care Clinics found. Showing 1 - 5
 Thomas P. Collins, Dds, A Pc Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 1321 S Eliseo Dr, Greenbrae, CA 94904 Phone: 415-461-5926 Fax: 415-461-6857 |
Mark Michna, Dds, Inc. Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 599 Sir Francis Drake Blvd, Suite 306, Greenbrae, CA 94904 Phone: 415-461-5351 Fax: 415-461-4614 |
Gila C. Dorostkar, Dds, Pc Dentist - Pediatric Dentistry Medicare: Not Enrolled in Medicare Practice Location: 1300 S Eliseo Dr, Suite 100, Greenbrae, CA 94904 Phone: 415-461-0414 Fax: 416-461-0431 |
Jason Sherman Dds, A Dental Corporation Dentist Medicare: Not Enrolled in Medicare Practice Location: 1321 S Eliseo Dr, Greenbrae, CA 94904 Phone: 323-972-8076 |
Eric Zaremski, Dds, Inc. Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 1000 S Eliseo Dr, Suite 202, Greenbrae, CA 94904 Phone: 415-461-3141 Fax: 415-461-6252 |
News Archive
World needs a business plan to end AIDS
In this post in Global Post's "Global Pulse" blog, Mitchell Warren, executive director of AVAC, a leading HIV prevention advocacy organization, and Chris Collins, vice president and director of public policy at amfAR, the Foundation for AIDS Research, write that "the world needs a business plan to end AIDS."
FDA grants orphan drug status to new 'Trojan Horse' like Ewing's Sarcoma drug
The Cure Our Children Foundation, a nonprofit charitable foundation dedicated to children, announced today that the U.S. Food and Drug Administration (FDA) has approved the Orphan Drug Designation of the foundation's unique drug product for children with Ewing's Sarcoma cancer. The efforts to develop this drug were made possible by the generous volunteers and researchers in private industry and at two universities.
Polypectomy is costly and unnecessary
Polypectomy (the surgical removal of polyps by colonoscopy) of small polyps found during CT colonography is costly and unnecessary according to a study performed at the University of Wisconsin School of Medicine and Public Health in Madison, WI.
Discovery Laboratories gets notice of noncompliance from Nasdaq Stock Market related to minimum bid price
Discovery Laboratories, Inc. announced today that, on June 29, 2015, the Company received a letter from The Nasdaq Stock Market indicating that, because the Company's common stock has not maintained a minimum closing bid price of $1.00 per share over the previous 30 consecutive business days, the Company is no longer in compliance with Nasdaq's Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement").
› Verified 3 days ago